Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Anti-Cancer Drugs|April 17, 2014
Risk factors for the development of pulmonary oil embolism after transcatheter arterial chemoembolization of hepatic tumorsGeng-Chin Wu, Edward D Chan, Yu-Ching Chou, et al.
Biomedicines|July 29, 2025
Correction: Cheng et al. NICEFIT-A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan. <i>Biomedicines</i> 2022, <i>10</i>, 2362Shih-Lung Cheng, Chau-Chyun Sheu, Chih-Feng Chian, et al.
Respirology (Carlton, Vic.)|February 6, 2019
Bidirectional association between tuberculosis and sarcoidosisSheng-Huei Wang, Chi-Hsiang Chung, Tsai-Wang Huang, et al.
Biomedicines|October 27, 2022
NICEFIT-A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in TaiwanShih-Lung Cheng, Chau-Chyun Sheu, Chih-Feng Chian, et al.
Journal of Cancer|August 17, 2019
Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with <i>EGFR</i>-mutated non-small-cell lung cancer - A multicenter prospective SMILE studyYu-Feng Wei, Wen-Tsung Huang, Tu-Chen Liu, et al.
Plos One|May 16, 2024
Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancerGee-Chen Chang, Jin-Yuan Shih, Chong-Jen Yu, et al.
Scientific Reports|August 21, 2024
Immune killer cells treatment for previously treated stage IV NSCLC patientsYen-Han Tseng, Ching-Liang Ho, Chih-Feng Chian, et al.
Cells|March 10, 2022
Accelerated Wound Healing and Keratinocyte Proliferation through PI3K/Akt/pS6 and VEGFR2 Signaling by Topical Use of Pleural FluidChen-Liang Tsai, Chih-Ying Changchien, Ying Chen, et al.
The Lancet. Respiratory Medicine|June 2, 2020
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trialYi-Long Wu, Ying Cheng, Jianying Zhou, et al.
The Lancet. Respiratory Medicine|December 2, 2023
Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort studyGee-Chen Chang, Chao-Hua Chiu, Chong-Jen Yu, et al.
Pageof 5